Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 331 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Observational data collection Clear all

Conditions: Mucopolysaccharidosis II
Interventions: Not listed
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Aging
Interventions: Mobile Service Robot, Survey; Device · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiac Pacemaker, Cardiac Rhythm Disorder, Bradycardia
Interventions: AVEIR remote care system; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Newport Beach, California

Conditions: Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
Interventions: Sample collection and Questionnaire; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years to 18 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor
Interventions: ABSK061; Drug
Lead sponsor: Abbisko Therapeutics Co, Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Childhood Acute Myeloid Leukemia, Childhood Burkitt Lymphoma, Childhood Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Informational Intervention, Interview, Medical Chart Review, Questionnaire Administration; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 31
States / cities: Oakland, California • Wilmington, Delaware • Fort Myers, Florida + 23 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY948862), Others except finerenone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 238,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Plaque Reduction
Interventions: MoodBrush Digital Application; Device
Lead sponsor: University of Southern California; Other
Eligibility: 3 Years to 6 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
Interventions: Treatment of transthyretin (ATTR) amyloidosis in observational study setting; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 33
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 24 more

Conditions: Infertility
Interventions: Eeva™ Test; Device
Lead sponsor: Progyny, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Chicago, Illinois • Carmel, Indiana • Iowa City, Iowa + 3 more

Conditions: Graft Versus Host Disease
Interventions: medical chart review, quality-of-life assessment; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Scottsdale, Arizona • Rochester, Minnesota • Cleveland, Ohio + 1 more

Conditions: Preeclampsia (PE)
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 6,550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Glendale, Arizona • Newark, Delaware • Miami, Florida + 15 more

Conditions: Sarcoma
Interventions: Interview, Observations, Guided Activities; Behavioral
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 7 Years to 11 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Nonverbal Communication, Critical Illness
Interventions: Aim 1 - VidaTalk - post-extubation, Aim 2 - VidaTalk - intubated, Aim 3 - VidaTalk tablet app, Aim 3 - attention-control with non-VidaTalk tablet; Other · Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Graft vs. Host Disease, GVHD, cGVHD, Graft Versus Host Disease in Skin
Interventions: Axatilimab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Myelodysplatic Syndromes, Myeloproliferative Neoplasm
Interventions: Caris Chromoseq; Diagnostic Test
Lead sponsor: Caris Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Liver
Interventions: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatobiliary Cancers
Interventions: Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings; Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more

Conditions: Coronary Disease
Interventions: Not listed
Lead sponsor: Elutia Inc.; Industry
Eligibility: Not listed
Enrollment: 1,420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 43
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 36 more

Conditions: Data Collection
Interventions: Not listed
Lead sponsor: GRAIL, Inc.; Industry
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Breast Cancer
Interventions: Blood draw and questionnaires; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 609 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Data Capture, Electronic Medical Record; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Survey; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Milk Collection, Nutrition Disorder, Infant
Interventions: No intervention; Other
Lead sponsor: Augusta University; Other
Eligibility: Not listed
Enrollment: 20 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Augusta, Georgia

Search by objective public record fields.

Mucopolysaccharidosis Type II Natural History

Affordable Mobile Robots for the Elderly

AVEIR Remote Care System Non-Significant Risk Study

Morphological Markers of Gastroesophageal Reflux Disease (GERD)

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology

An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States

Digital vs. Parent Modeled Toothbrushing

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Eeva System Imaging Study

Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)

Non-Invasive Preeclampsia Screening and Biobank

A Qualitative Case Study of the Experiences of Children With Cancer as They Learn About Their Diagnosis and Treatment

Vidatalk Communication Application: Usability, Acceptability and Efficacy Study

Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease

Caris Chromoseq Data Collection

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

Observational Study Protocol: LIVER-R

Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)

The Galleri® Community Research Program

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies

Improving Prison Health Equity Through Cancer Literacy and Screening Awareness in Florida

Analysis of Donor Milk